

Press release

MEDICA S.P.A.**INVESTMENT OF 20% IN THE SHARE CAPITAL OF THE NEWLY ESTABLISHED COMPANY MEDICO MEDTECH CO LTD**

Medolla (MO), 15 January 2024 – Medica S.p.A., an integrated Italian biomedical and MedTech group with a strong international footprint, announces that it has invested with a 20% stake in the share capital of the newly established company Medico MedTech Co. Ltd, trading company based in Suzhou - China, whose majority shareholder is Suzhou Huisheng Medical Science & Technology Co. Ltd and the other minority shareholder is Shanghai Hotin Trading Co. Ltd, for a total consideration of 7 million RMB.

Thanks to this investment, Medica will have a direct presence in the Chinese market which will allow it to strengthen its market share in a complex territory, especially within the Chronic division, and to better face the commercial challenges that will arise in a territory with strong development by bringing together the high technological skills of Medica with the strong product registration skills of the partner Huisheng and the commercial skills of the partner Hotin.

Luciano Fecondini President of Medica SpA commented “This investment represents a fundamental step in the strategic strengthening of Medica in China and envisages long-term cooperation with the two partners Suzhou Huisheng Medical Science & Technology Co. Ltd and Shanghai Hotin Trading Co. Ltd.”.

Medica Profile

Medica Group is operating since 1985 in the biomedical district of Mirandola (Italy). Development of innovative products for blood purification has always been company's core business. Thanks to the activity of two extremely dynamic R&D groups (medical equipment, membranes and disposable), the Group competes successfully in several markets, namely:

- **Medical** (dialysis, CRRT, ECCO2, Apheresis, DFPP, CHF, HIPEC, pre-transplant organ perfusion, bioregenerative medicine, gastroenterology, urodynamics, oxygen humidification).
- **Microbiological purification of water**
- **Industrial automation** for the biomedical sector.

R&D focus has been integrated over the years with a highly automated production systems in several facilities, and with different commercial entities, both in Italy and abroad.

The key success factors of the Group are:

- **extrusion of hollow fiber membranes** for hemofiltration, plasmapheresis, cascade filtration, oxygen humidification, ultrafiltration and microfiltration of water

- **vertical integration**, proved by the ability to manage not only the design and development of medical disposables and equipment, and the development of the automation technologies required for their production as well.
- **International recognition with significant share of export**, with sales in over 60 countries.

The Medica group closed its consolidated financial statements for 2022 with revenues of 50.9 million euros (43.8 million euros in 2021), EBITDA of 11.2 million euros (9.9 million euros in 2021), EBIT of € 5.3 million (€ 5.8 million in 2021) and net profit of € 4.0 million (€ 5.0 million in 2021).

For information:

Investor Relations Medica

Giovanni Plasmati

(+39) 0535 51159

giovanni.plasmati@medica-spa.com

Euronext Growth Advisor

CFO SIM S.p.A.

(+39) 02 303431

ecm@cfosim.com